Caplin Point Laboratories Ltd.
NSE: CAPLIPOINTCaplin Point Laboratories Ltd.: A 30-second snapshot
Caplin Point Laboratories (CAPLIPOINT) trades at 1998.80, up 15.42% over the past 3 months following a strong FY26 result with revenue of 2303 Cr (+13.2% YoY) and PAT growth of 20.1%. The stock is above both its 50-DMA (1704.78) and 200-DMA (1902.79), though RSI of 72.1 signals overbought momentum, and the stock remains 16.54% below its 52-week high.
P/E
23.9
Forward P/E
17.9
ROE
—
Debt / Equity
0.17
Profit Margin
+29.3%
Div. Yield
+0.4%
5Y ROE > 15%
4/5
5Y FCF > 0
4/5
Quality
74/100
News
6 headlines · 6 positive · 0 negative
CAPLIPOINT: FY26 revenue up 13.2% and PAT up 20.1%, with robust cash reserves and no debt - TradingView
TradingView
CAPLIPOINT: FY26 revenue grew 13.2% YoY to ₹2,303 Cr, PAT up 20.1%, with strong margins and cash flow - TradingView
TradingView
Caplin Point Laboratories March-Quarter Consol Net Profit 1.7 Bln Rupees - TradingView
TradingView
CAPLIPOINT: Strong growth, high margins, and robust cash position drive expansion in U.S. and LATAM markets - TradingView
TradingView
CAPLIPOINT: Strong growth, high margins, and robust cash flow drive expansion in key global markets - TradingView
TradingView
Recent context
- ·FY26 annual results released mid-May 2026 showed revenue of 2303 Cr (+13.2% YoY) and PAT growth of 20.1%, with commentary citing expansion in U.S. and LATAM markets and a strong cash position with no reported debt.
- ·All 6 tracked news items from May 14, 2026 are positively coded and relate to the FY26 earnings release; news flow is concentrated in a single event window with no adverse headlines in the dataset.
- ·The stock reclaimed its 200-DMA (1902.79) during the 3-month rally from near 1704 support, and currently trades approximately 17% above the 50-DMA.
Strengths
- +PE of 23.87 is the lowest among 6 tracked sector peers (vs. Cipla 29.78, Dr. Reddys 26.66, Sun Pharma 41.32, Apollo Hospitals 64.50), with forward PE at 17.92 implying market expectation of earnings expansion.
- +Profit margin of 29.34% and 5-year earnings CAGR of 18.3% reflect a sustained profitability track record; FY26 PAT growth of 20.1% is consistent with that long-run rate.
- +Quality score of 60 ranks 1st of 6 sector peers; FCF positive in 4 of available years and a consistency score of 83 indicate relative earnings reliability.
- +D/E of 0.166 is low relative to pharma capital-intensity norms; May 2026 results commentary highlights no debt and robust cash reserves, consistent with the balance sheet data.
Weaknesses
- −RSI at 72.1 places the stock in overbought territory; nearest support levels are at 1764.20, 1747.00, and 1704.40 between 8% and 15% below current price.
- −Debt trend is rising despite a currently low absolute D/E (0.166); ongoing U.S. and LATAM expansion capex could continue this trajectory.
- −Analyst coverage consists of a single data point (rating: 1 on a 1-5 scale, lower = more constructive); no statistically meaningful sell-side consensus exists for this stock.
- −1-year price return of 3.08% is modest relative to the 3-month surge of 15.42%, indicating the stock traded flat-to-weak for much of FY26 before the post-result move.
Open questions
- ?Does the 29.34% profit margin reflect a durable competitive position in LATAM and U.S. generics, or is it partially a function of the current regulatory and pricing environment in those geographies?
- ?How has the rising debt trend interacted with FCF generation over the last 3 years, and at what D/E level would capex requirements meaningfully pressure the balance sheet?
- ?Given that all current news is concentrated around a single earnings event, what is the track record of operating performance in the quarters following strong annual results?
- ?Does the PE discount relative to large-cap pharma peers (Cipla, Sun Pharma, Dr. Reddys) reflect a structural size and liquidity discount, or has it historically compressed toward sector median during earnings re-rating periods?
Peer comparison: Pharma
Ranks 1 of 6 on quality| Symbol | Name | P/E | ROE | Quality |
|---|---|---|---|---|
| CAPLIPOINT | Caplin Point Laboratories Ltd.You're viewing | 23.9 | — | 60 |
| Industry avg | across 5 peers | 46.9 | +11.8% | 37 |
| MAXHEALTH | Max Healthcare Institute Ltd. | 72.4 | — | 54 |
| SUNPHARMA | Sun Pharmaceutical Industries Ltd. | 41.3 | — | 50 |
| APOLLOHOSP | Apollo Hospitals Enterprise Ltd. | 64.5 | — | 42 |
| CIPLA | Cipla Ltd. | 29.8 | +11.7% | 24 |
| DRREDDY | Dr. Reddy's Laboratories Ltd. | 26.7 | +11.8% | 17 |
Technical state
Current price
₹1,998.80
SMA 50
₹1,704.78
SMA 200
₹1,902.79
RSI (14)
72.1 (overbought)
From 52w high
-16.5%
1Y return
+3.1%
3M return
+15.4%
50-DMA
Above
200-DMA
Above
Algorithmic support levels
Risk flags
- mediumRSI at 72.1 is in overbought territory; price has risen 15.42% over the past 3 months, extending above both the 50-DMA (1704.78) and 200-DMA (1902.79).
- mediumDebt trend is rising (D/E currently 0.166); while absolute leverage remains low for a pharma company, the directional increase warrants monitoring against the capex cycle required for U.S. and LATAM market expansion.
- lowAnalyst coverage is very sparse: only 1 analyst tracked on a 1-5 scale. No statistically meaningful consensus can be derived from a single data point.
- lowPeer ROE data is missing for 4 of 5 listed sector peers, and 1-year price-change data is unavailable for all peers, limiting the quality of relative performance and valuation comparisons.
Cross-section contradictions
- FY26 fundamentals show 13.2% revenue growth, 20.1% PAT growth, and positive news sentiment (6 of 6 articles positive), yet the 12-month price return is only 3.08% vs. a 3-month return of 15.42%, suggesting appreciation is concentrated in the post-earnings window rather than distributed across the full year.
- Quality score of 60 ranks 1st of 6 sector peers, and the stock trades at a PE of 23.87 below Cipla (29.78), Dr. Reddys (26.66), Sun Pharma (41.32), and Apollo Hospitals (64.50), a combination that does not follow the typical quality-premium relationship observed in pharma.
For informational purposes only. Not investment advice. VivaTrades is not a SEBI-registered Investment Adviser or Research Analyst. Market data sourced from public feeds; consult a registered adviser before any investment decision.
Fundamentals & technicals: refreshed 25 Jun 2026 · refreshed daily at 01:00 IST
AI synthesis (narrative, snapshot, strengths/weaknesses, peer ranking): generated 17 May 2026 · rotates through NIFTY 500 every ~5 days